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Abstract 
Background: In the Netherlands, from 2007 to 2009, 3,522 Q-fever cases were 
notified from three outbreaks. These are the largest documented outbreaks in the 
world. Previous studies suggest that symptoms can persist for a long period of time, 
resulting in a reduced quality of life (QoL). The aim of this study was to qualify and 
quantify the health status of Q-fever patients after long-term follow-up.  
Methods: 870 Q-fever patients of the 2007 and 2008 outbreaks were mailed a 
questionnaire 12 to 26 months after the onset of illness. We assessed demographic 
data and measured health status with the Nijmegen Clinical Screening Instrument 
(NCSI). The NCSI consists of three main domains of functional impairment, 
symptoms and QoL that are divided into eight sub-domains. The NCSI scores of Q-
fever patients older than 50 years (N=277) were compared with patients younger than 
50 years (N= 238) and with norm data from healthy individuals (N=65) and patients 
with chronic obstructive pulmonary disease (N=128).  
Results: The response rate was 65.7%. After applying exclusion criteria 515 Q-fever 
patients were included in this study. The long-term health status of two thirds of Q-
fever patients (both younger and older than 50 years) was severely affected for at least 
one sub-domain. Patients scores were most severely affected on the sub-domains 
general QoL (44.9%) and fatigue (43.5%). Hospitalisation in the acute phase was 
significantly related to long-term behavioural impairment (OR 2.8, CI 1.5-5.1), poor 
health related QoL (OR 2.3,CI 1.5-4.0) and subjective symptoms (OR 1.9, CI 1.1-
3.6). Lung or heart disease, depression and arthritis significantly affected the long-
term health status of Q-fever patients.  
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Conclusions: Q-fever patients presented 12 to 26 months after the onset of illness 
severe -clinically relevant- subjective symptoms, functional impairment and impaired 
QoL. All measured sub-domains of the health status were impaired. Hospitalisation 
and co-morbidity were predictors for worse scores. Our data emphasise that more 
attention is needed not only to prevent exposure to Q-fever but also for the prevention 
and treatment of the long-term consequences of this zoönosis. 
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Background  
Q-fever is a worldwide zoönotic disease caused by Coxiella burnetii (C. burnetii), an 
obligate intracellular bacterium. Until 2007 Q-fever was uncommon in the 
Netherlands, with 5-20 notified cases annually [1]. From 2007-2009, 3,522 cases were 
notified in three large outbreaks [2], with dairy goats implicated as the source [1,2]. 
The majority of Q-fever patients (80%) reside in the southern province of Noord-
Brabant [1,2,3]. Between 2007 and early 2010 some hard-hit communities suffered a 
cumulative incidence of 2,650 notified Q-fever cases per 100,000 inhabitants (one in 
38 people).  
In general 60% of infected Q-fever patients are asymptomatic, while 20% develop 
mild symptoms [4]. The remaining 20% of Q-fever patients present with more severe 
symptoms ranging from high fever, severe headache, night sweating, nausea and 
diarrhoea, to pneumonia, hepatitis, pericarditis, myocarditis and neurological 
symptoms. [5]. Chronic Q-fever may develop in 1.5-5% of acute cases, due to 
reactivation of C. burnetii [4,6,7]. A feared complication is endocarditis, which may 
take 10-15 years to develop. In particular pregnant women and patients with heart 
valve disorders, vascular prosthesis and impaired immunity have a higher risk to 
develop chronic infection [4,6,7]. Protracted fatigue up to 10 years after infection 
[8,9] is another late sequel. A Post-Infection Fatigue Syndrome (PIFS) [9] may also 
occur after other infections such as Lyme disease [10]. In 10-15% of Q-fever patients 
fatigue can last up to 5-10 years [11] and is referred to as Post Q-fever fatigue 
Syndrome (PQFS). Other authors [8,9] state higher percentages of fatigue. PQFS 
presents with symptoms resembling those of Chronic Fatigue Syndrome (CFS). 
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During the Dutch Q-fever outbreaks patients and general practitioners (GPs) 
repeatedly reported persisting symptoms to the public health authorities and in 
particular about fatigue. These signals could not be substantiated, as we lacked 
specific information on the health status at individual and at Q-fever patient 
population level. Furthermore, we were uncertain whether data from other small 
national [12] and international studies, would also apply to our large Dutch Q-fever 
cohorts. In order to assess the long-term health status of Dutch Q-fever patients we 
started this study.  
Long-term health status impairment may have a large impact on patients, their 
families and the societies that they are part of. In this study, the primary aim was to 
provide a detailed assessment of the health status of Q-fever patients 12 to 26 months 
after the onset of illness. This information will assist clinicians and patients to better 
understand the natural course, consequences of the disease and predictors for an 
affected health status. 
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Methods  
Q-Quest I study  
This cohort study is part of the collaborative Q-Quest I study, which aims to measure 
the impact of the Q-fever outbreaks in terms of population health and societal 
implications. The study started in May 2008 and includes studies on diagnostics, 
treatment, clinical symptoms, costs and the long-term health status. 
 
Study design and population 
Eligible for inclusion in this study were Q-fever patients notified in 2007 and 2008 to 
the Municipal Health Service “Hart voor Brabant” and “Brabant Zuid-Oost” with a 
first day of illness in 2007 or 2008. All patients fitted the Dutch notification criteria; a 
laboratory confirmation of Q-fever and clinical presentation of fever, pneumonia or 
hepatitis. Patients were diagnosed by 4 different laboratories. At the beginning of the 
outbreak in 2007 the laboratory test most frequently used was the CFT (complement 
fixation test). A sero-conversion or a fourfold increase in titre, between two 
subsequent tests with a minimum time interval of two to four weeks, was considered 
positive. Later during the outbreak one laboratory used the IFA (Immuno 
Fluorescence Assay). This latter test distinguished between phase I en II IgM and IgG 
[13]. 
Exclusion criteria were: an unknown onset of Q-fever infection, a questionnaire 
completed by another person or an incomplete questionnaire. Participants younger 
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than 18 years of age, were excluded because the questionnaire instruments were 
developed for adults.  
 
Questionnaires 
All patients that agreed to participate in the Q-Quest I study, received a questionnaire 
that comprised two parts: the cost and symptoms questionnaire which collected data 
on demographics, self reported symptoms, co morbidity, hospitalisation, healthcare 
consumption, education and employment and the Nijmegen Clinical Screening 
Instrument (NCSI) [14] to measure health status.  
The NCSI is based on an empirical definition of health status [15], covering 
physiological functioning, symptoms, functional impairment, and quality of life (Qol) 
as main domains. In this study we only measured the main domains symptoms, 
functional impairment and QoL. These main domains are subdivided into 8 sub-
domains: subjective symptoms; dyspnoea emotions; fatigue; behavioural impairment; 
subjective impairment; general Quality of Life (General QoL); Health Related Quality 
of Life (HRQoL); and satisfaction with relations [14]. Consult table 1 for definitions 
and instruments [15-20] of the sub-domains of health status measured by the NCSI. 
The NCSI provides normative data indicating normal functioning, mild - or severe 
problems for each sub-domain. The NCSI contains 8 sub-domains, each expressed as 
a single score on its own scale. Thus eight different scales were used. The score range 
indicating severe problems was based on patients with COPD attending a 
multidisciplinary inpatient pulmonary rehabilitation program (n= 128). The key 
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requirement for inclusion was severe problems in multiple areas of the health status. 
This decision was based on a three-day intake procedure, in which elaborate 
assessment, physiological tests and clinical interviews with seven medical disciplines 
were undertaken. The score range indicating normal functioning was based on a group 
of healthy subjects (n=65). Scores below the 80th percentile of healthy controls 
indicate the score range of normal functioning. Scores above the 20th percentile of the 
pulmonary rehabilitation group indicate the score range of severe problems. Higher 
NCSI scores indicate more problems. For more details see Peters et al [14]. 
 
Data collection 
In February 2009, 870 patients received a Q-Quest study information folder and a 
participation request form by post. Patients could state their willingness to take part in 
any of the Q-Quest I studies by signing the consent-form. All patients from the 2007 
cohort received a Q-Quest I questionnaire (12-26 months after onset of Q-fever 
illness) together with the consent form in February 2009. Patients from the 2008 
cohort, who had stated their willingness to participate, were mailed the questionnaire 
exactly one year after the month of onset of illness. If questionnaires were not 
returned within three weeks, patients from both cohorts received two reminders three 
weeks apart. See figure 1 for detailed information. 
The study design and protocol were approved by the local Medical Ethics Review 
Committee of the Jeroen Bosch Hospital. 
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Data analysis 
In this study we compared the Q-fever patients NCSI scores with those of the norm 
groups: healthy individuals (n=65) and the special group of severe COPD patients 
(n=128). 
Questionnaires were double scanned in November 2009. SPSS 15.0 for windows was 
used for statistical analysis. P-values were based on two tailed tests with P<0.05 
defined as significant. Chi-square test was used to compare proportions. Logistic 
regression and the general linear model were used to model outcomes (8 sub-domains 
of NCSI) for the three groups (healthy COPD-norm group and Q-fever patients), 
while controlling for the potential confounders: age, gender, smoking and education-
level. During logistic regression we regrouped the outcomes normal, mild and severe 
for the 8 sub-domains into normal and abnormal (combining mild and severe). 
Notification data of the Municipal Health Service enabled us to compare Q-fever 
respondents and non responders for year of onset of illness, age, gender and 
hospitalisation at the acute stage of the infection. As the control groups providing the 
normative data for the NCSI were older than 50 years, Q-fever patients younger than 
50 years of age were analyzed separately from patients older than 50 years. 
For comparison of participating Q-fever patients younger or older than 50 years of 
age, we also looked at co-morbidity and hospitalisation. These data were unavailable 
for healthy individuals and COPD patients.  
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Results  
Patient participation 
Of the 898 patients notified in 2007-2008, 28 were excluded due to incomplete data or 
unknown month of onset of illness (figure 1). Of the 5 patients that died, we lacked 
information on the cause of death. In total 572 questionnaires were received (65.7 %). 
Fewer men than women returned the questionnaire (responders vs. non-responders 
women 223/106, men 323/218 p=0.017). The response rate was higher for patients 
aged over 35 (P=0.011). After excluding participants younger than 18 years (n=9), 
participants who did not complete the questionnaire themselves (n=22) and 
incomplete questionnaires (n=26), 515 questionnaires were left (see figure 1). The 
mean interval between the first day of illness for Q-fever patients of cohort 2007 and 
cohort 2008 and filling out the questionnaire was 19.6 months (SD 2.3) and 11.6 
months (SD 1.0), respectively. 
 
Characteristics of the study population 
Q-fever patients, the healthy and COPD norm group were similar with respect to 
gender and level of education. The characteristics of the study population are 
presented in table 2.  
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Health status 
The long-term health status of Q-fever patients was severely affected especially for 
the sub-domains General QoL (44.9%) and fatigue (43.5%) (see figure 2). Almost two 
fifths of the Q-fever patients (38.2%) older than 50 years, had severe problems on 
more than one sub-domain (see figure 3). Of the Q-fever patients with abnormal 
fatigue, 79.5% also reported abnormal scores on subjective symptoms, 77.9% on 
behavioural impairment, 65.0% on HRQoL, 60.7% on dyspnoea emotions and 57.7% 
on General QoL. 
Female Q-fever patients consistently reported abnormal functioning (mild and severe 
on the sub-domains of the NCSI) more frequently than males. This difference was 
only significant for satisfaction with relations (34.0% of the women vs. 28.1% of the 
men, p=0.012). 
No significant differences were found for 7 sub-domain scores between Q-fever 
patients older and younger than 50 years. Although the frequency with which 
dyspnoea was reported was similar for the age groups (45.8% >50 years n=277 and 
42.9% <50 years n=238) patients younger than 50 years suffered more often from 
dyspnoea emotions (OR 2.0, CI 1.3-3.1 p=0.001). 
In comparison to the healthy norm score, Q-fever patients showed significantly more 
abnormal health status (mild and severe) in 7 of the 8 sub-domains (see table 3). The 
worst scores were found for the sub-domains fatigue, subjective symptoms and 
subjective impairment. Q-fever patients had significantly lower (healthier) scores in 
all 8 NCSI-sub-domains, compared to the COPD-norm score. 
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The year of onset of illness, level of education and smoking behaviour had no 
significant influence on sub-domain mean scores. However, patients that were 
hospitalised (23.6% of patients older than 50 years) during the onset of illness or with 
underlying heart or lung disease, arthritis and depression scored significantly worse 
for several sub-domains (see table 4). The outcomes for patients younger than 50 
years were similar. 
Heart disease increased the risk for an abnormal outcome for the sub-domains 
subjective symptoms, behavioural and subjective impairment, HR QoL and dyspnoea 
emotions. Lung disease had a negative influence on the outcome of the first three 
aforementioned domains.  
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Discussion  
The present study is the largest and longest follow-up study of Dutch Q-fever patients 
of the 2007 and 2008 outbreaks. Using a validated questionnaire, the Nijmegen 
Clinical Screening Instrument (NCSI), we provided a detailed assessment of the long-
term effects of Q-fever on health status 12-26 months after onset of illness. The most 
important finding of this study was that, in two thirds of Q-fever patients of all ages, 
at least one sub-domain was severely (clinically) affected up to 26 months after the 
initial illness. The sub-domains General QoL (44.9%) and fatigue (43.5%) were most 
frequently severely affected.  
Published data on health status, and its sub-domains, in Q-fever patients are scarce. 
Hatchette reported [21] that 52% of Q-fever patients were symptomatic and had an 
impaired QoL 27 months after infection, with significant lower scores on five of eight 
domains of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), 
as compared to non-infected controls. Impaired domains were: physical pain, physical 
function, emotional role, physical role and social function. 
In our study we found 58.9% of patients with abnormal (mild and severe) fatigue. 
This is similar to other publications that state 68.7% [9] five and 64.9 % [8] protracted 
fatigue up to ten to years after infection. Unfortunately we were unable to establish if 
Q fever patients mainly suffered fatigue the first year and later recovered as we only 
had contact with patients once. The fact that we found no differences between patients 
of the 2007 and 2008 cohorts is suggestive of persisting complaints. 
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Some studies state that cytokine deregulation and immuno-modulation from 
persistence of C. burnetii, might be responsible [22] for prolonged fatigue, but others 
contradict this [23].  
Other studies find prolonged impairment of the health status months after 
legionellosis and pneumonia. Dutch pneumonia patients had significantly affected SF-
36 scores 18 months after pneumonia on the subscales physical function and general 
health status [24]. Survivors of a Legionnaires Disease-outbreak in the Netherlands 
reported 17 months after infection severely impaired SF-36-domains: physical role 
function, general health and vitality [25]. Up to 75.0% of patients reported fatigue 
[25]. Although all three infectious diseases seem to cause long-term impairment; the 
impaired sub-domains differ.  
The severity of initial illness in general negatively influences the long-term QoL 
[26,27]. Similarly, the severity of the acute Q-fever symptoms predicts long-term 
symptoms [28]. Our study shows that hospitalised patients more often scored 
abnormal on the sub-domains HRQoL, behavioural impairment and subjective 
symptoms than those that were not hospitalised during the acute phase of illness. We 
consider hospitalisation to be an indicator of the severity of the initial infection. Our 
assumption that Q-fever patients with severe acute illness are more likely to 
experience long-term impaired QoL was therefore proven correct. Another study 
shows that patients that had been admitted to the Intensive Care Unit – regardless of 
the cause – have an impaired QoL (SF-36) up to 18 months [29]. 
General QoL (44.9%) and fatigue (43.5%) were severely affected in our study 
subjects. A small study on Dutch Q-fever patients that measured the one year follow-
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up and also used the NCSI reported a higher rate of 53% of patients with severe 
fatigue [12]. We suspect that the patients in that study had a higher hospitalisation rate 
and presented with more pneumonia than our patients. Consultation of our notification 
data confirmed this presumption, but the difference was marginal. Furthermore, 
proportionally more patients in that study might have been recruited from the local 
hospital’s chest clinic. In the present study, we approached all patients in the region, 
regardless of the severity of the initial disease. 
We found that heart disease increased the risk of subjective symptoms, behavioural 
and subjective impairment, HR QoL and dyspnoea emotions. Whereas lung disease 
negatively influenced the outcomes of the first three of these sub-domains.  
Other authors stated that underlying heart [30,31] or lung disease [32], arthritis [33], 
depression [34] and diabetes [35], all had a negative effect on the health status in 
different sub-domains. We also found this effect, except for diabetes, but could not 
compare data with existing studies, as most of these studies focus on specific diseases 
(such as COPD) and grades of severity. We however, combined all diseases of a 
certain tract.  
 
Methodological considerations and study limitations 
The NCSI is not widely used in Q-fever research. This makes comparison to other 
QoL-research in Q-fever difficult. The advantage of the NCSI is that it provides a 
detailed assessment including many domains of health status covering symptoms, 
functional impairment and quality of life. The NCSI provides more and specific 
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information on sub-domains than some of the other instruments such as the SF-36. 
Furthermore, the availability of datasets of both a COPD and a healthy norm group 
for the NCSI, enabled us to compare the health status of Q-fever patients with these 
two groups. Such a comparison provides useful information for GPs and medical 
specialists in their understanding of Q-fever patients. Another advantage is that the 
NCSI questionnaire for the domain fatigue is based on the CIS (Checklist Individual 
Strength). This instrument corrects for normal fatigue [36]. As many Q-fever patients 
suffer from fatigue, the NCSI seemed the right choice.  
The municipal health service regularly received Q-fever patient reports of continuing 
respiratory complaints. We therefore looked for a norm group with a known 
respiratory component that we could compare these Q-fever patients with. When we 
compared data from Q-fever patients with the NCSI norm group of COPD patients it 
should be realized that this is a specific subgroup of COPD patients with a severely 
impaired health status in multiple sub-domains. We made the choice to use this COPD 
norm group as we wished to compare the long-term health status of Q-fever patients 
(who often suffered a pneumonia initially) with another group of patients with a 
known impaired health status.  
The healthy control group was rather small with 65 individuals all over 50 years of 
age. However, the number of controls provided sufficient power for us to show a large 
and clear difference between the groups.  
Normative data of healthy subjects and those with COPD were only available for 
patients over 50 years of age. This was unfortunate as 46.2 % of Q-fever patients were 
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younger than 50. As we chose our method to be as strict and transparent as possible, 
we presented data for patients over and under 50 separately. 
In at least 1.6% of the Q-fever patients in the Dutch 2007-2008 cohorts, the condition 
became chronic (van der Hoek et al, submitted for publication). For our study 
population this could potentially mean eight or nine patients with chronic Q-fever. As 
not all patients in our study were followed up serologically we were unable to 
establish if and who developed chronic Q-fever or any of its presentations such as 
endocarditis.  
Data were collected during the early stages of the Q-fever outbreaks in the 
Netherlands. At that stage there was little to no media attention for these outbreaks. 
The general public was mostly unaware of Q-fever and the possible negative long-
term outcome. Patients were not medicalised and mostly unaware. We therefore 
believe that our data were not negatively influenced by the media or the general 
knowledge of the patient of the negative long-term outcomes.  
 
Implications 
By assessing the long-term health status of Q-fever patients of the largest outbreak in 
the world, we are able to describe and quantify the impact of Q-fever on patient’s 
lives. Hospitalisation is an important predictor of severe illness, poor long-term health 
status outcome and long-term absence from work (unpublished data G.Morroy). 
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The outbreaks are continuing and Q-fever has become endemic in the area. Since 
symptoms could last for ten years or more [8], the burden of disease for the affected 
communities is likely to be considerable. 
A better understanding of long-term outcomes is essential for policy makers dealing 
with these outbreaks. GPs and other Medical Doctors should be aware that Q-fever 
patients may present with long-term symptoms especially in those that were 
hospitalised and or with co-morbidity (heart-, lung-disease, and depression). 
Knowledge of these detrimental long-term outcomes should help MDs to be more 
supportive to these patients and refer promptly and adequately to specialist care. 
 
Conclusions  
Our study of the largest described Q-fever cohort in the world shows a large long-
term impact of Q-fever on the health status of Q-fever patients of all ages. This is but 
an indication of the burden of disease in the years to come considering the more than 
4,000 reported Dutch Q-fever cases since 2007. Policy makers ought to take the long-
term burden of disease into account, when considering measures to be taken to curb 
these extensive Dutch outbreaks. We recommend further research to develop adequate 
prevention, treatment and revalidation guidelines that might benefit these affected 
patients. 
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Figures 
Figure 1. Flowchart; Response rate of 898 Q-fever patients with onset of disease in 
2007 and 2008 
Figure 2. The 8 sub-domain scores of Q-fever patients older (n= 277) and younger 
than 50 years of age (N=238). 
Figure 3. Percentage of Q-fever patients with the number of severely affected 
domains of the health status. 
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Table 2. Characteristics of the study population: Q-fever patients younger and 
older than 50 years, Norm groups Chronic Obstructive Pulmonary Disease- and 
healthy individuals. Q-fever patients >50 currently smoke significantly more than 
COPD-controls. None of the other characteristics differ significantly (logistic 
regression). 
Q-fever Total Characteristics 
 Age <50 >50 yrs 
COPD- Healthy 
 
 N=238 (%) N=277 (%) N=128 (%) N=65 (%) N=708 
Gender          
  Male 140 (58.8) 166 (59.9) 86 (67.2) 47 (72.3) 439 
  Female 98 (41.2) 111 (40.1) 42 (32.8) 18 (27.7) 269 
Age          
  Mean 40.4  60.3  62.5  63.5   56.7 
  SD 7.4  7.6  6.9  6.6   
Current smoking         
  Yes 96 (40.3) 71 (26.6) 11 (8.9) 11 (16.9) 189 
  No 137 (57.6) 196 (73.4) 113 (91.1) 54 (83.1) 500 
Education-level          
  Low  56 (23.5) 97 (35.5) 62 (50.4) 20 (30.8) 235 
  Average 120 (50.4) 126 (46.2) 38 (30.9) 26 (40.0) 310 
  High 60 (25.2) 50 (18.3) 23 (18.7) 19 (29.2) 152 
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Table 3. Comparison 8 NCSI sub-domains scores between Q-fever patients > 50 
years and the healthy norm group. Abnormal is a combination of mild and severe 
scores. Used method chi square. 
Domain and 
subdomain 
Q-fever 
n=277 (%) 
Healthy control   
n=65 (%) 
Q-fever vs. healthy(ref)   
OR (CI)                    P value 
Symptoms     
  Subjective symptoms    
    N 255 65   
    Normal  123 (48.2) 59 (90.8)    
    Abnormal 132 (51.8) 6 (9.2) 9.9 (4.0-24.5) 0.000 
  Dyspnoea emotions    
    N 172 65   
    Normal  103 (59.9) 55 (84.6)   
    Abnormal 69 (40.1) 10 (15.4) 3.1 (1.4-6.8) 0.006 
  Fatigue     
    N 207 65   
    Normal  85 (41.1) 57 (87.7)   
    Abnormal 122 (58.9) 8 (12.3) 9.2 (4.0-20.8) 0.000 
Functional impairment    
  Behavioural impairment    
    N 277 65   
26 
 
    Normal  126 (45.5) 49 (75.4)   
    Abnormal 151 (54.5) 16 (24.6) 3.8 (1.9-7.3) 0.000 
 Subjective impairment    
    N 249 65   
    Normal  173 (69.5) 60 (92.3)   
    Abnormal  76 (30.5) 5 (7.7) 5.0 (1.9-13.4) 0.001 
Quality of life    
  General Quality of Life    
    N 234 65   
    Normal  129 (55.1) 51 (78.5)   
    Abnormal 105 (44.9) 14 (21.5) 2.4 (1.2-4.7) 0.011 
  Health related Quality of Life    
    N 271 65   
    Normal  151 (55.7) 55 (84.6)   
    Abnormal 120 (44.3) 10 (15.4) 3.7 (1.8-7.7) 0.001 
  Satisfaction relations    
    N 252 65   
    Normal  166 (65.9) 37 (56.9)   
    Abnormal 86 (34.1) 28 (43.1) 0.5 (0.3-0.9) 0.040 
2
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